Anal cancer
Osteoarthritis: significant improvement in pain and physical function with Tanezumab
Results from a phase 3 study evaluating Tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis ( OA...
Combined modality treatment associated with improved overall survival in pediatric Hodgkin lymphoma patients
Research from Rutgers Cancer Institute of New Jersey ( Unined States ) has shown improved overall survival at five years...
Atezolizumab associated with Bevacizumab in non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with sarcomatoid differentiation
Non-clear cell renal cell carcinoma ( NccRCC ) and clear cell renal cell carcinoma with sarcomatoid differentiation ( sccRCC )...
Ibrance: FDA has expanded approved use of metastatic breast cancer treatment to include male patients
The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...
Venclexta as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukemia patients, approved by FDA
The U.S. Food and Drug Administration ( FDA ) has approved Venclexta ( Venetoclax ) in combination with Obinutuzumab (...
FDA has approved Piqray, the first PI3K inhibitor for HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...
AACR 2019: Gilteritinib in patients with FLT3-mutated acute myeloid leukemia
Patients assigned to Gilteritinib ( Xospata ) were found to have a 36% reduction in risk of death compared with...
Fecal transplant effective against immunotherapy-induced colitis
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis...
Inflammatory bowel disease in childhood associated with increased risk of cancer
The increased risk of cancer persists into adulthood, and has not fallen since the introduction of modern drug therapies for...
Postmenopausal women: quitting smoking is associated with reduced risk of bladder cancer
Although bladder cancer is a fairly rare cancer type, representing an estimated 4.6% of new cancer cases in 2019, it...
Pembrolizumab, an immunotherapy drug, found safe in treating cancer patients with HIV
The results of a study has shown that patients living with HIV and one of a variety of potentially deadly...
Immunotherapy: two checkpoint inhibitors generate responses against castration-resistant metastatic prostate cancer
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have...
Lynparza tablets for the treatment of Platinum-sensitive relapsed ovarian cancer regardless of BRCA status: approved in European Union
The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for...
European Commission has approved Cabometyx for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma
The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...
Olaparib in combination with Abiraterone delays disease progression in metastatic castration-resistant prostate cancer
Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...
Non-metastatic castration-resistant prostate cancer: Enzalutamide delays metastasis-free survival versus placebo without worsening HRQoL in PROSPER trial
The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide (...
Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer, approved in European Union
The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...
ADXS-PSA plus Pembrolizumab in metastatic castration-resistant prostate cancer: KEYNOTE-046
ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...
Nivolumab plus Platinum-doublet chemotherapy vs chemotherapy as first-line treatment for advanced non-small cell lung cancer with less than 1% tumor PD-L1 expression: CheckMate 227
CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab...
Nivolumab plus Ipilimumab versus Platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: safety analysis from CheckMate 227
CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy...